Compare GeneDx Holdings Corp (WGS) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs Zillow Group Inc Class C — how do they compare? GeneDx Holdings Corp trades at $67.33 (market cap $2.02B), while Zillow Group Inc Class C trades at $29.01 (market cap $6.59B). The key difference: Zillow Group Inc Class C is far larger — about 3.3× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GeneDx Holdings Corp for 19 Days and Zillow Group Inc Class C for 38 Days on average.
| WGS | Z | |
|---|---|---|
Market Cap | $2.02B | $6.59B |
Volume | 734,640 | 9,134,294 |
Sector | Health | Media |
52-Week High | $167.51 | $78.04 |
52-Week Low | $34.51 | $27.13 |
Typical Hold Time | 19 Days | 38 Days |
Enterprise Value | $2.05B | $6.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Zillow Group (Z) trades at $29.01, up 6.34% in the past 24 hours, showing strong momentum despite mixed technical signals. The company demonstrates improving fundamentals with revenue growth from $2.2B in 2024 to $2.6B in 2025 and a return to profitability with $23M net income. Recent earnings show two consecutive beats against expectations, though the stock faces headwinds from elevated mortgage rates and housing market volatility.
The outlook remains cautiously optimistic with analyst consensus price target of $60.33 suggesting significant upside potential. However, investors face risks from housing market sensitivity to interest rates and competitive pressures. The company's transition to an integrated transaction platform and AI integration present growth opportunities, but execution risks and market conditions warrant careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
